In 2023, the FDA approved the combination of trastuzumab and tucatinib for HER2-positive, chemotherapy-refractory, RAS wild-type unresectable, or metastatic colorectal cancer [75]. This evidence concerns the gene ERBB2 and metastatic colorectal cancer.